Nothing Special   »   [go: up one dir, main page]

CN111848454B - Histone deacetylase 6 inhibitor and preparation method and application thereof - Google Patents

Histone deacetylase 6 inhibitor and preparation method and application thereof Download PDF

Info

Publication number
CN111848454B
CN111848454B CN201910347227.6A CN201910347227A CN111848454B CN 111848454 B CN111848454 B CN 111848454B CN 201910347227 A CN201910347227 A CN 201910347227A CN 111848454 B CN111848454 B CN 111848454B
Authority
CN
China
Prior art keywords
compound
reaction
histone deacetylase
inhibitor
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910347227.6A
Other languages
Chinese (zh)
Other versions
CN111848454A (en
Inventor
张颖杰
徐文方
高倩文
赵春龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong University
Original Assignee
Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong University filed Critical Shandong University
Priority to CN201910347227.6A priority Critical patent/CN111848454B/en
Publication of CN111848454A publication Critical patent/CN111848454A/en
Application granted granted Critical
Publication of CN111848454B publication Critical patent/CN111848454B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a histone deacetylase 6 inhibitor, and a preparation method and application thereof. The histone deacetylase 6 inhibitor has a structure shown in the following general formula (I). The invention also provides a preparation method of the compound and application of the compound in preparing a medicament for preventing or treating diseases related to abnormal activity or expression of HDAC 6.

Description

Histone deacetylase 6 inhibitor and preparation method and application thereof
Technical Field
The invention relates to a histone deacetylase 6(HDAC6) inhibitor, and a preparation method and application thereof, and belongs to the technical field of organic compound synthesis and medical application.
Background
Unlike other Histone Deacetylase (HDAC) members, HDAC6 is a histone deacetylase (CD1 and CD2) containing only two catalytic domains, distributed mainly in the cytoplasm rather than the nucleus, and has no significant role in the post-translational modification of histones, but is mainly involved in regulating the acetylation status of non-histones such as α -tubulin (α -tubulin), cortical actin (cortictin), heat shock protein 90(HSP-90) and peroxiredoxins I/II (peroxiredoxins I/II). An increasing number of studies have shown that HDAC6 is a potential therapeutic target for tumors, autoimmune diseases and neurodegenerative diseases (Kalin, j.h.etc. j.med.chem.2013,56, 6297-. In the field of tumor therapy, two reversible inhibitors of HDAC6 (ACY-1215 and ACY-241) have entered clinical research (Rodrigues, D.A.etc. Mini.Rev.Med.chem.2016,16, 1175-1184). However, the selectivity of HDAC6 of the two compounds is not high, and is only about 10 times higher than that of HDAC1/2/3 (Rodrigues, d.a.etc. mini.rev.med.chem.2016,16,1175-1184), so that the toxic and side effects caused by inhibiting other HDAC subtypes cannot be completely avoided.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a histone deacetylase 6(HDAC6) inhibitor, and a preparation method and application thereof.
The technical scheme of the invention is as follows:
inhibitors of histone deacetylase 6(HDAC6)
A histone deacetylase 6(HDAC6) inhibitor having the following structural formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof:
Figure BDA0002042759220000011
wherein: x is a side chain of various amino acids;
y is
Figure BDA0002042759220000012
Z is
Figure BDA0002042759220000021
R is aliphatic hydrocarbon, aromatic hydrocarbon or hydrogen;
is in the S or R configuration, or a racemate thereof.
Preferred according to the invention, wherein:
x is
Figure BDA0002042759220000022
Y is
Figure BDA0002042759220000023
Z is in para-or meta-position of the benzene ring
Figure BDA0002042759220000024
R is
Figure BDA0002042759220000025
Or H;
is in the S configuration;
further preferably, the compound is one of the following:
Figure BDA0002042759220000026
Figure BDA0002042759220000031
Figure BDA0002042759220000041
Figure BDA0002042759220000051
Figure BDA0002042759220000061
II, preparation method of histone deacetylase 6(HDAC6) inhibitor
The preparation method of the histone deacetylase 6(HDAC6) inhibitor comprises the following steps:
carrying out methyl esterification reaction on an initial raw material L-amino acid 1a-1c in methanol to obtain an intermediate 2a-2c, condensing a Boc-L-amino acid 3a-3c with cyclopentanol, then removing a protecting group to obtain an intermediate 4a-4c, carrying out condensation reaction and oxidation reaction on p-hydroxymethylbenzoic acid or m-hydroxymethylbenzoic acid and O- (tetrahydro-2H-pyran-2-yl) hydroxylamine to obtain a key intermediate 7a-7b, then carrying out reductive amination reaction on the key intermediate and the intermediate 2a-2c,4a-4c, and then removing the protecting group from HCl/EtOAc to obtain a hydroxamic acid target compound 8 a-8L; p-hydroxymethylbenzoic acid or m-hydroxymethylbenzoic acid is taken as a raw material, a key intermediate 9a-9b is obtained through a condensation reaction, (Boc)2O protection and an oxidation reaction with O-phenylenediamine, then the key intermediate and the intermediate 2a-2c,4a-4c are subjected to a reductive amination reaction, then a protective group is removed through HCl/EtOAc to obtain a target compound 10a-10l of the O-phenylenediamine, and a hydrolysis reaction is carried out on the compound 10d-10f to obtain a compound 11a-11 c;
the synthetic route is as follows:
Figure BDA0002042759220000071
reagents and reaction conditions in the above synthetic route: a) thionyl chloride, methanol; b) cyclopentanol, (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, triethylamine, dichloromethane; HCl/EtOAC; c) the method comprises the following steps O- (tetrahydro-2H-pyran-2-yl) hydroxylamine or O-phenylenediamine, (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, triethylamine, dichloromethane; d): manganese dioxide, dichloromethane; e) the method comprises the following steps Di-tert-butyl dicarbonate, triethylamine and dichloromethane; f) the method comprises the following steps Compound 2a-2c or 4a-4c, triethylamine, sodium cyanoborohydride, glacial acetic acid and methanol/tetrahydrofuran with the volume ratio of 1: 1; HCl/EtOAC; g) lithium hydroxide and methanol/water in a volume ratio of 1: 1.
According to a preferred embodiment of the present invention, the preparation of histone deacetylase 6(HDAC6) inhibitor compounds 8a-8l, 10a-10l, 11a-11c, exemplified by compounds 8a,10a,11a, respectively, comprises the following steps:
(1) preparation of intermediate 2a methyl (S) -2-amino-2-phenylacetate hydrochloride
Dissolving 10mmol of L-phenylglycine (1a) in 50mL of anhydrous methanol at 0 ℃, dropwise adding 40mmol of thionyl chloride, after the addition is completed, stirring the solution at 0 ℃ for 0.5 hour, then heating at 75 ℃ for 6 hours, removing the solvent when the completion of the reaction is confirmed by TLC, recrystallizing the residue with ethyl acetate, filtering, and drying to obtain compound 2 a;
compounds 2b-2c were prepared in analogy to Compound 2 a;
(2) intermediate 4a preparation of cyclopentyl (S) -2-amino-2-phenylacetate hydrochloride
To a solution of Boc-L-phenylglycine 2.0mmol (3a) dissolved in 20mL of anhydrous dichloromethane at 0 deg.C was added 2.4mmol EDCI, 2.4mmol HOBT and 2.4mmol triethylamine; after the addition was complete, the mixture was stirred at 0 ℃ for 0.5 h, then 2.4mmol cyclopentanol was added, then the solution was warmed to 25 ℃ and stirred for 12h, the solvent was removed and the residue was diluted with ethyl acetate and washed twice with 1M citric acid, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution in that order; the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to give a yellow oil; to the resulting yellow oil was added HCl/EtOAc 5mL and stirred at 25 ℃ for 4 hours, the product precipitated, filtered and dried in vacuo to give compound (4 a);
compounds 4b-4c were prepared in a similar manner to Compound 4 a;
(3) preparation of intermediate 6a 4- (hydroxymethyl) -N- ((tetrahydro-2H-pyran-2-yl) oxy) benzamide
After 5.0mmol of compound 5a (and 6.0mmol of EDCI were dissolved in 50mL of dichloromethane at 25 deg.C, 5.0mmol of O- (tetrahydro-2H-pyran-2-yl) hydroxylamine was added at 0 deg.C, the mixture was stirred at 25 deg.C, and when the reaction was complete, the solvent was removed under vacuum, the resulting residue was diluted with ethyl acetate, washed twice with saturated aqueous sodium chloride solution, the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated, and dried under vacuum to give compound 6 a;
compound 6b was prepared in analogy to compound 6 a;
(4) intermediate 6c preparation of N- (2-aminophenyl) -4- (hydroxymethyl) benzamide
10mmol of compound 5a are dissolved in 80mL of dichloromethane at 25 ℃ and 12mmol of EDCI and 12mmol of triethylamine are added; the mixture was stirred at 0 ℃ for 0.5 h, then 12mmol of o-phenylenediamine was added to the solution and stirred at 25 ℃ for 15 h; filtering the crude product, and recrystallizing with ethyl acetate to obtain a compound 6 c;
compound 6d was prepared similarly to compound 6 c;
(5) preparation of intermediate 7a 4-formyl-N- ((tetrahydro-2H-pyran-2-yl) oxy) benzamide
3.98mmol of compound 6a are dissolved in 40mL of dichloromethane at 25 ℃ and 59.69mmol of manganese dioxide are slowly added; after the addition was complete, the mixture was stirred for a further 6 hours, after the reaction was complete, the mixture was filtered through celite, concentrated and concentrated by passing PE/EA ═ 1:1, purifying by column chromatography to obtain a compound 7 a;
compounds 7b,9a-9b were prepared in analogy to Compound 7 a;
(6) preparation of intermediate 7c tert-butyl (2- (4- (hydroxymethyl) benzoylamino) phenyl) carbamate
Dissolving 2.9mmol of compound 6c and 3.5mmol of triethylamine in 10mL of dichloromethane at 0 ℃, dissolving 3.5mmol of BOC anhydride in 10mL of tetrahydrofuran and adding dropwise to dichloromethane, after the addition, stirring the mixture at 25 ℃ for 12 hours, then removing the solvent under reduced pressure, diluting the residue with ethyl acetate, and washing with water, 1M citric acid and saturated aqueous sodium chloride solution in sequence; drying the organic layer over anhydrous magnesium sulfate, filtering, concentrating and purifying by column chromatography to give compound 7 c;
compound 7d was prepared similarly to compound 7 c;
(7) preparation of Compound 8a cyclopentyl (S) -2- ((4- (hydroxycarbamoyl) benzyl) amino) -2-phenylacetate hydrochloride
At 25 ℃, 0.86mmol of compound 7a and 1.0mmol of compound 4a are added to 20mL of a solution of 1:1 in a tetrahydrofuran/methanol mixed solvent, then adding 1.0mmol of triethylamine, stirring the mixture at 50 ℃ for 0.5 hour, then adding 1.72mmol of sodium cyanoborohydride and one drop of glacial acetic acid, stirring the solution at 25 ℃ for 6 hours, after the reaction is finished, removing the solvent and diluting the residue with ethyl acetate, and washing the residue twice with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution in turn; the organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography to give a colorless oil; to the resulting oil was added 4mL HCl/EtOAc and stirred at 25 ℃ for 6 h, the product precipitated and was filtered and dried to give a light red solid as the hydrochloride salt;
compounds 8b-8l were prepared in analogy to Compound 8 a;
(8) preparation of Compound 10a cyclopentyl (S) -2- ((4- ((2-aminophenyl) carbamoyl) benzyl) amino) -2-phenylacetate hydrochloride
At 25 ℃, 0.44mmol of compound 9a and 0.53mmol of compound 4a are added to 20mL of a solution of 1:1 in tetrahydrofuran/methanol mixed solvent, then 0.53mmol of triethylamine is added, the mixture is stirred at 50 ℃ for 0.5 hour, then 1.1mmol of sodium cyanoborohydride and one drop of glacial acetic acid are added, the solution is stirred at 25 ℃ for 6 hours, after the reaction is finished, the solvent is removed and the residue is diluted with ethyl acetate, washed twice with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution in sequence, the organic layer is dried with anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography to obtain colorless oil, 4mL of HCl/EtOAc is added to the obtained oil and stirred at 25 ℃ for 6 hours, the product is precipitated and filtered, and dried to obtain light red solid as hydrochloride;
compounds 10b-10l were prepared in analogy to Compound 10 a;
(9) preparation of compound 11a (S) -2- ((4- ((2-aminophenyl) carbamoyl) benzyl) amino) -2-phenylacetic acid
At 25 ℃, dissolving 0.32mmol of compound 8e in 10mL of methanol/water mixed solvent with the volume ratio of 1:1, adding 3.2mmol of lithium hydroxide, refluxing at 65 ℃ for 1 hour after the addition is finished, concentrating the reaction solution after the reaction is finished, adjusting the pH to 6 by using 1M hydrochloric acid, filtering, and drying in vacuum to obtain an off-white solid;
compounds 11b-11c were prepared in a similar manner to compound 11 a.
The above steps can be optimized by those skilled in the art to improve the yield, and they can make synthetic routes according to the basic knowledge in the art, such as selecting reactants, solvents and temperature, and can improve the yield by using various protecting groups to avoid side reactions. These conventional protection methods can be found in T.Greene, Protecting Groups in Organic Synthesis.
Application of histone deacetylase 6(HDAC6) inhibitor
The invention also provides an application of the histone deacetylase 6(HDAC6) inhibitor in preparing a medicament for preventing or treating diseases related to abnormal activity or expression of HDAC 6;
the diseases related to the abnormal activity or expression of the HDAC6 are various tumors, autoimmune diseases and neurodegenerative diseases.
The tumors comprise melanoma, multiple myeloma and the like, the autoimmune diseases comprise rheumatoid arthritis, inflammation and the like, and the neurodegenerative diseases comprise Alzheimer disease, Parkinson syndrome and the like.
In addition, the invention also includes a pharmaceutical composition suitable for oral or parenteral administration, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to the invention and one or more pharmaceutically acceptable carriers or excipients.
The invention has the beneficial effects that:
the compound has a novel structure, shows a strong HDAC6 inhibition effect, has antiproliferative activity on U266, can remarkably enhance the antiproliferative activity of Bortezomib on U266 cells by combining with a marketed proteasome inhibitor Bortezomib, and shows a strong chemosensitization effect, so that the compound can be used for preparing a medicament for preventing or treating diseases related to abnormal expression or activity of HDAC 6.
Detailed Description
The present invention will be further described with reference to the following examples, but is not limited thereto.
Example 1 preparation of Compounds 8a-8l, exemplified by Compound 8a
The specific synthetic method and steps are as follows:
(1) preparation of intermediate 2a methyl (S) -2-amino-2-phenylacetate hydrochloride
L-phenylglycine (1a, 1.51g, 1.0eq, 10mmol) was dissolved in 50mL of anhydrous methanol at 0 deg.C, and thionyl chloride (2.9mL, 4.0eq, 40 m) was added dropwisemol), after the addition was complete, the solution was stirred at 0 ℃ for 0.5 h and then heated at 75 ℃ for 6 h. When the reaction was complete as determined by TLC, the solvent was removed, the residue was recrystallized from ethyl acetate, filtered, and dried to give compound 2a as a white solid (1.71g, 86% yield).1H NMR(400MHz,DMSO-d6)δ9.32–9.08(m,3H),7.56–7.50(m,2H),7.49-7.43(m,3H),5.26(s,1H),3.71(s,3H).
Compounds 2b-2c were prepared in analogy to Compound 2 a.
(2) Intermediate 4a preparation of cyclopentyl (S) -2-amino-2-phenylacetate hydrochloride
To a solution of Boc-L-phenylglycine (3a, 0.50g, 1.0eq, 2.0mmol) dissolved in 20mL of anhydrous dichloromethane at 0 deg.C were added EDCI (0.48g, 1.2eq, 2.4mmol), HOBT (0.33g, 1.2eq, 2.4mmol) and triethylamine (0.24g, 1.2eq, 2.4 mmol). After the addition was complete, the mixture was stirred at 0 ℃ for 0.5 h, then cyclopentanol (0.21g, 1.2eq, 2.4mmol) was added. The solution was then warmed to 25 ℃ and stirred for an additional 12 hours. The solvent was removed and the residue was diluted with ethyl acetate and washed twice with 1M citric acid, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution in that order. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to give a yellow oil. To the resulting yellow oil was added HCl/EtOAc (5mL) and stirred at 25 ℃ for 4 h. The product was precipitated, filtered and dried in vacuo to give compound (4a) as a white solid (0.28g, 55% yield).1H NMR(400MHz，DMSO-d6)δ8.94(s，3H)，7.49-7.46(m，5H)，5.26-5.15(m，2H)，1.90-1.30(m，8H)。
Compounds 4b-4c were prepared in a similar manner to compound 4 a.
(3) Preparation of intermediate 6a 4- (hydroxymethyl) -N- ((tetrahydro-2H-pyran-2-yl) oxy) benzamide
Compound 5a (0.75g, 1.0eq, 5.0mmol) and EDCI (1.15g, 1.2eq, 6.0mmol) were dissolved in dichloromethane (50mL) at 25 deg.C, O- (tetrahydro-2H-pyran-2-yl) hydroxylamine (0.59g, 1.0eq, 5.0mmol) was added at 0 deg.C, and the mixture was stirred at 25 deg.C. When the reaction is deemed complete, the solvent is removed under vacuum and the residue obtainedDiluted with ethyl acetate and washed twice with saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and dried in vacuo to give compound 6a as a colorless oil (1.0g, 80% yield).1H NMR(400MHz，DMSO-d6)δ11.61(s，1H)，7.73(d，J＝8.0Hz，2H)，7.40(d，J＝8.0Hz，2H)，5.33(t，J＝5.8Hz)，1H)，4.99(t，J＝3.0Hz，1H)，4.55(d，J＝5.6Hz，2H)，4.09-4.03(m，1H)，3.55-3.51(m，1H)，1.75-1.70(m，3H)，1.60-1.51(m，3H)。
Compound 6b was prepared in analogy to compound 6 a.
(4) Preparation of intermediate 7a 4-formyl-N- ((tetrahydro-2H-pyran-2-yl) oxy) benzamide
Compound 6a (1.0g, 1.0eq, 3.98mmol) was dissolved in dichloromethane (40mL) at 25 deg.C and manganese dioxide (5.2g, 15.0eq, 59.69mmol) was added slowly. After the addition was complete, the mixture was stirred for an additional 6 hours. After the reaction was complete, the mixture was filtered through celite, concentrated and purified by column chromatography (PE/EA ═ 1:1) to give compound 7a as a colorless oil (0.66g, 67% yield).1H NMR(400MHz，DMSO-d6)δ11.88(s，1H)，10.08(s，1H)，8.01(d，J＝8.1Hz，2H)，7.96(d，J＝8.1Hz，2H)，5.04(t，J＝3.2Hz，1H)，4.10-4.02(m，1H)，3.57-3.52(m，1H)，1.81-1.68(m，3H)，1.64-1.50(m，3H)。
Compound 7b was prepared in analogy to compound 7 a.
(5) Preparation of Compound 8a cyclopentyl (S) -2- ((4- (hydroxycarbamoyl) benzyl) amino) -2-phenylacetate hydrochloride
Compound 7a (0.22g, 1.0eq, 0.86mmol) and Compound 4a (0.25g, 1.2eq, 1.0mmol) were added to 20mL of a tetrahydrofuran/methanol (1:1) mixed solvent at 25 deg.C, then triethylamine (0.1g, 1.2eq, 1.0mmol) was added, the mixture was stirred at 50 deg.C for 0.5 hour, then sodium cyanoborohydride (0.11g, 2.0eq, 1.72mmol) and one drop of glacial acetic acid were added, and the solution was stirred at 25 deg.C for 6 hours. After the reaction was completed, the solvent was removed and the residue was diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution in this orderNext, the process is carried out. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography to give a colorless oil. To the resulting oil was added HCl/EtOAc (4mL) and stirred at 25 ℃ for 6 h, the product precipitated and was filtered off and dried to give a pale red solid as the hydrochloride salt (0.15g, 54% yield).1H NMR(400MHz,DMSO-d6)δ11.33(s,1H),10.54(s,1H),10.31(s,1H),9.10(s,1H),7.79(d,J＝8.0Hz,2H),7.57(d,J＝7.4Hz,4H),7.53–7.46(m,3H),5.24(s,1H),5.15(t,J＝5.8Hz,1H),4.17(d,J＝13.0Hz,1H),4.04–3.94(m,1H),1.85-1.78(m,1H),1.76-1.63(m,2H),1.61–1.34(m,5H).13C NMR(101MHz,DMSO-d6)δ167.58,164.14,133.57,133.46,130.42,129.98,129.63,129.34,128.97,127.55,79.84,62.67,49.48,32.27,23.56,23.45.HRMS(AP-ESI)m/z calcd for C21H24N2O4[M+H]+369.1814,found 369.1810.
Compounds 8b-8l were prepared in analogy to Compound 8 a.
Example 2 preparation of Compounds 10a-10l, exemplified by Compound 10a
The specific synthetic method and steps are as follows:
(1) intermediate 6c preparation of N- (2-aminophenyl) -4- (hydroxymethyl) benzamide
Compound 5a (1.52g, 1.0eq, 10mmol) was dissolved in 80mL of dichloromethane at 25 deg.C, followed by the addition of EDCI (2.30g, 1.2eq,12mmol) and triethylamine (1.21g, 1.2eq,12 mmol). The mixture was stirred at 0 ℃ for 0.5 h, then o-phenylenediamine (1.3g, 1.2eq,12mmol) was added to the solution and stirred at 25 ℃ for 15 h. The crude product was filtered and recrystallized from ethyl acetate to give compound 6c as a pale yellow solid (0.76g, 31% yield).1H NMR(400MHz,DMSO-d6)δ9.63(s,1H),7.95(d,J＝7.9Hz,2H),7.44(d,J＝7.9Hz,2H),7.17(d,J＝7.8Hz,1H),6.97(td,J＝7.6,1.5Hz,1H),6.78(dd,J＝8.0,1.4Hz,1H),6.60(td,J＝7.6,1.4Hz,1H),5.33(t,J＝5.7Hz,1H),4.89(s,2H),4.58(d,J＝5.6Hz,2H).
Compound 6d was prepared in analogy to compound 6 c.
(2) Preparation of intermediate 7c tert-butyl (2- (4- (hydroxymethyl) benzoylamino) phenyl) carbamate
Compound 6c (0.70g, 1.0eq, 2.9mmol) and triethylamine (0.36g, 1.2eq, 3.5mmol) were dissolved in 10mL of dichloromethane at 0 ℃, the BOC anhydride (0.76g, 1.2eq, 3.5mmol) was dissolved in 10mL of tetrahydrofuran and added dropwise to dichloromethane, after which the mixture was stirred at 25 ℃ for 12 hours, then the solvent was removed under reduced pressure, the residue was diluted with ethyl acetate and washed with water, 1M citric acid and saturated aqueous sodium chloride solution in that order. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography to give compound 7c as a colorless oil (0.85g, 86% yield).1H NMR(400MHz,DMSO-d6)δ9.81(s,1H),8.70(s,1H),7.92(d,J＝8.0Hz,2H),7.56(dd,J＝7.7,1.8Hz,1H),7.52(dd,J＝7.9,1.6Hz,1H),7.47(d,J＝7.9Hz,2H),7.22-7.13(m,2H),5.36(t,J＝5.7Hz,1H),4.59(d,J＝5.5Hz,2H),1.45(s,9H).
Compound 7d was prepared in analogy to compound 7 c.
(3) Intermediate 9a preparation of tert-butyl (2- (4-formylbenzoylamino) phenyl) carbamate
Compounds 9a-9b were prepared in analogy to compound 7 a.
9a, white solid (0.20g, 70% yield).1H NMR(400MHz,DMSO-d6)δ10.13(s,1H),10.00(s,1H),8.73(s,1H),8.15(d,J＝8.0Hz,2H),8.07(d,J＝8.0Hz,2H),7.59–7.51(m,2H),7.22(td,J＝7.7,1.7Hz,1H),7.16(td,J＝7.6,1.6Hz,1H),1.44(s,9H).
(4) Preparation of Compound 10a cyclopentyl (S) -2- ((4- ((2-aminophenyl) carbamoyl) benzyl) amino) -2-phenylacetate hydrochloride
Compound 9a (0.15g,1.0eq, 0.44mmol) and compound 4a (0.14g, 1.2eq, 0.53mmol) were added to 20mL of a tetrahydrofuran/methanol (1:1) mixed solvent at 25 deg.C, then triethylamine (0.05g, 1.2eq, 0.53mmol) was added, the mixture was stirred at 50 deg.C for 0.5 hour, then sodium cyanoborohydride (0.07g, 2.5eq, 1.1mmol) and a drop of glacial acetic acid were added, and the solution was stirred at 25 deg.C for 6 hours. After the reaction was complete, the solvent was removed and the residue was diluted with ethyl acetate, successively with saturated aqueous sodium bicarbonate solution andthe mixture was washed twice with saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography to give a colorless oil. To the resulting oil was added HCl/EtOAc (4mL) and stirred at 25 ℃ for 6 h, the product precipitated and was filtered off and dried to give a pale red solid as the hydrochloride salt (0.12g, 53% yield).1H NMR(400MHz,DMSO-d6)δ10.57(s,1H),8.16(d,J＝8.0Hz,2H),7.66(d,J＝8.0Hz,2H),7.60-7.57(m,3H),7.53-7.51(m,3H),7.47–7.41(m,1H),7.35-7.29(m,,2H),5.27(s,1H),5.19-5.15(m,1H),4.23(d,J＝13.2Hz,1H),4.04(d,J＝13.6Hz,1H),1.89–1.29(m,8H).13C NMR(101MHz,DMSO-d6)δ167.52,165.56,135.52,134.60,131.56,130.95,130.81,130.47,129.66,129.43,128.66,127.75,126.96,124.09,79.86,62.64,49.06,32.27,23.58,23.47.HRMS(AP-ESI)m/z calcd for C27H29N3O3[M+H]+444.2287,found 444.2285.
Compounds 10b-10l were prepared in analogy to compound 10 a.
Example 3 preparation of Compounds 11a-11c, exemplified by Compound 11a
Preparation of compound 11a (S) -2- ((4- ((2-aminophenyl) carbamoyl) benzyl) amino) -2-phenylacetic acid
Compound 10d (0.15g,1.0eq,0.32mmol) was dissolved in 10mL of methanol/water (1:1) mixed solvent at 25 ℃, lithium hydroxide (0.14g,10eq,3.2mmol) was added, after the addition was completed, reflux was carried out at 65 ℃ for 1 hour, after the reaction was completed, the reaction solution was concentrated, pH was adjusted to 6 with 1M hydrochloric acid, filtered, and dried under vacuum to give an off-white solid (85mg, 71% yield).1H NMR(400MHz,DMSO-d6)δ9.67(s,1H),7.96(d,J＝7.9Hz,2H),7.47(d,J＝8.0Hz,2H),7.44–7.30(m,5H),7.17(d,J＝7.8Hz,1H),7.00-6.96(m,1H),6.79(dd,J＝8.1,1.4Hz,1H),6.65–6.57(m,1H),4.97(s,2H),4.22(s,1H),3.82(d,J＝3.1Hz,2H).
Compounds 11b-11c were prepared in a similar manner to compound 11 a.
Example 4 evaluation of in vitro HDAC inhibitory Activity of target Compounds
We have measured the inhibitory activity of HDAC6 and HeLa nuclear extracts (mainly containing HDAC1 and HDAC2) of the target compounds using fluorescence analysis, using the approved non-selective HDAC inhibitor SAHA on the market as a positive control.
The experimental results (table 1) show that the compounds 8a-8f of the present invention exhibit strong inhibition of HDAC6, wherein 8a-8d have superior inhibitory activity on HDAC6 than the non-selective HDAC inhibitor SAHA. More importantly, 8a-8f, 8g, 8i and 8l have excellent HDAC6 selectivity compared to SAHA.
TABLE 1 results of evaluation of HDAC inhibitory Activity in vitro
Figure BDA0002042759220000141
Figure BDA0002042759220000151
Figure BDA0002042759220000161
Figure BDA0002042759220000171
aND:Not determined
Example 5 in vitro anti-proliferation assay of human multiple myeloma U266 cells with a Compound of interest
Tumor cells with a certain density are inoculated on a 96-well plate, after the cells are cultured in a cell culture box for 12 hours, test drugs with different concentrations are added, the cells are continuously cultured for 48 hours, 20 mu L of MTT is added into each well, after the cells are incubated for 4 hours, culture solution in the wells is carefully discarded, formazan formed by dissolving DMSO is added, and the absorbance is measured by a microplate reader, so that the cell antiproliferative activity of the test drugs is measured.
From the results in Table 2, it can be seen that compounds 8a-8f all have antiproliferative activity on U266, and although 8a-8f have weaker antiproliferative activity on U266 than the non-selective HDAC inhibitor SAHA, the antiproliferative activity of compounds 8a-8c,8f on U266 is better than that of the reported selective inhibitor Tubastatin A of HDAC 6.
TABLE 2 in vitro antiproliferation of U266 cells by target Compoundsa
Figure BDA0002042759220000172
Figure BDA0002042759220000181
aValues are expressed as the mean of three independent replicates. The SD value is less than 20% of the average value.
Example 6 in vitro anti-proliferative assay of Compounds 8a-8f in combination with the marketed proteasome inhibitor Bortezomib on human multiple myeloma U266 cells
To further investigate the anti-tumor activity of the compounds of interest, we tested the antiproliferative activity of compounds 8a-8f on U266 cells in combination with the marketed proteasome inhibitor Bortezomib. Cells were pretreated with 5. mu.M of 8a-8f followed by 48h of Bortezomib. The experimental results show (table 3) that compounds 8a-8f all significantly enhanced the antiproliferative activity of Bortezomib on U266 cells. Among them, compounds 8a-8c,8f showed very strong chemosensitization. Compared with Tubastatin A, a reported HDAC6 selective inhibitor, the compounds 8a-8c,8f have stronger Bortezomib sensitization.
TABLE 3 antiproliferative test of combination on U266a
Figure BDA0002042759220000182
aValues are expressed as the mean of three independent replicates. The SD value is less than 20% of the average value.
bIC by administration of Bortezomib alone50Divided by the corresponding combination50To calculate the sensitization factor.

Claims (7)

1. A histone deacetylase 6 inhibitor having the following structural formula (I), a pharmaceutically acceptable salt thereof:
Figure FDA0002981316440000011
wherein:
x is
Figure FDA0002981316440000012
Y is
Figure FDA0002981316440000013
Z is in para-or meta-position of the benzene ring
Figure FDA0002981316440000014
R is
Figure FDA0002981316440000015
Or H;
is in the S configuration.
2. The histone deacetylase 6 inhibitor according to claim 1, which is one of the following compounds:
Figure FDA0002981316440000016
Figure FDA0002981316440000021
Figure FDA0002981316440000031
Figure FDA0002981316440000041
Figure FDA0002981316440000051
3. the method for preparing the histone deacetylase 6 inhibitor according to claim 1, comprising the following steps:
carrying out methyl esterification reaction on an initial raw material L-amino acid 1a-1c in methanol to obtain an intermediate 2a-2c, condensing a Boc-L-amino acid 3a-3c with cyclopentanol, then removing a protecting group to obtain an intermediate 4a-4c, carrying out condensation reaction and oxidation reaction on p-hydroxymethylbenzoic acid or m-hydroxymethylbenzoic acid and O- (tetrahydro-2H-pyran-2-yl) hydroxylamine to obtain a key intermediate 7a-7b, then carrying out reductive amination reaction on the key intermediate and the intermediate 2a-2c,4a-4c, and then removing the protecting group from HCl/EtOAc to obtain a hydroxamic acid target compound 8 a-8L; p-hydroxymethylbenzoic acid or m-hydroxymethylbenzoic acid is taken as a raw material, a key intermediate 9a-9b is obtained through a condensation reaction, (Boc)2O protection and an oxidation reaction with O-phenylenediamine, then the key intermediate and the intermediate 2a-2c,4a-4c are subjected to a reductive amination reaction, then a protective group is removed through HCl/EtOAc to obtain a target compound 10a-10l of the O-phenylenediamine, and a hydrolysis reaction is carried out on the compound 10d-10f to obtain a compound 11a-11 c;
the synthetic route is as follows:
Figure FDA0002981316440000061
reagents and reaction conditions in the above synthetic route: a) thionyl chloride, methanol; b) cyclopentanol, (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, triethylamine, dichloromethane; HCl/EtOAC; c) the method comprises the following steps O- (tetrahydro-2H-pyran-2-yl) hydroxylamine or O-phenylenediamine, (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, triethylamine, dichloromethane; d): manganese dioxide, dichloromethane; e) the method comprises the following steps Di-tert-butyl dicarbonate, triethylamine and dichloromethane; f) the method comprises the following steps Compound 2a-2c or 4a-4c, triethylamine, sodium cyanoborohydride, glacial acetic acid and methanol/tetrahydrofuran with the volume ratio of 1: 1; HCl/EtOAC; g) lithium hydroxide and methanol/water in a volume ratio of 1: 1.
4. Use of a histone deacetylase 6 inhibitor according to claim 1 or 2 for the preparation of a medicament for the prevention or treatment of a disease associated with abnormal HDAC6 activity or expression.
5. The use according to claim 4, wherein the disease associated with abnormal HDAC6 activity or expression is a tumor, an autoimmune disease or a neurodegenerative disease.
6. The use of claim 5, wherein the tumors are melanoma, multiple myeloma; the autoimmune disease is rheumatoid arthritis and inflammation; the neurodegenerative disease is Alzheimer disease and Parkinson syndrome.
7. A pharmaceutical composition suitable for oral or parenteral administration comprising a histone deacetylase 6 inhibitor of claim 1 or 2 and one or more pharmaceutically acceptable carriers or excipients.
CN201910347227.6A 2019-04-28 2019-04-28 Histone deacetylase 6 inhibitor and preparation method and application thereof Active CN111848454B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910347227.6A CN111848454B (en) 2019-04-28 2019-04-28 Histone deacetylase 6 inhibitor and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910347227.6A CN111848454B (en) 2019-04-28 2019-04-28 Histone deacetylase 6 inhibitor and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN111848454A CN111848454A (en) 2020-10-30
CN111848454B true CN111848454B (en) 2021-05-07

Family

ID=72964894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910347227.6A Active CN111848454B (en) 2019-04-28 2019-04-28 Histone deacetylase 6 inhibitor and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN111848454B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116924959A (en) * 2022-03-30 2023-10-24 山东大学 HDAC11 subtype selective inhibitor and preparation method and application thereof
CN115521228B (en) * 2022-09-26 2023-08-22 中国药科大学 BChE and HDAC double-target inhibitor and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614223B2 (en) * 2010-11-16 2013-12-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
CN102898332B (en) * 2011-07-25 2015-05-06 中国医学科学院医药生物技术研究所 Hydroxamic acid derivative, its pharmaceutical composition, preparation method and application
CN109020921B (en) * 2018-07-10 2020-08-04 山东大学 Histone deacetylase HDAC6 inhibitor and preparation method and application thereof

Also Published As

Publication number Publication date
CN111848454A (en) 2020-10-30

Similar Documents

Publication Publication Date Title
AU2021204209B2 (en) Processes and intermediates in the preparation of C5aR antagonists
KR100637110B1 (en) Cell adhesion inhibitors
JP3555876B2 (en) N-aroylphenylalanine derivative
AU780385B2 (en) Tyrosine derivatives
DE69133463T2 (en) Retrovirus protease inhibitors
DE60033689T2 (en) INHIBITORS OF SERIN PROTEASES
CN101723896B (en) Tyrosine derivative histone deacetylases inhibitor and application thereof
JPH06502859A (en) Retroviral protease inhibitors
BR112012027062B1 (en) compound, process for the preparation of a compound and uses of it
CN111848454B (en) Histone deacetylase 6 inhibitor and preparation method and application thereof
JPH11503422A (en) Succinic acid derivatives that inhibit proteases
CN105884767A (en) 9-substituted pyridino-[3,4-b]indole derivative, preparation method thereof and application thereof as SIRT protein inhibitor
US20040254221A1 (en) Novel Nitrogenous Compound and use thereof
CN107810189B (en) Process for the preparation of nitrogen mustard derivatives
CN114685382B (en) Quinazoline-4-amine derivative with HDACs inhibitory activity, and preparation method and application thereof
US5763464A (en) Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
Dahlgren et al. New inhibitors of the malaria aspartyl proteases plasmepsin I and II
WO2002070467A1 (en) Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
CN115677704B (en) Histone deacetylase 6 inhibitor containing 7H-pyrrolo [2,3-d ] pyrimidine structure, and preparation method and application thereof
RU2722694C1 (en) Method of producing n-((hydroxyamino)-oxoalkyl)-2-(quinazolin-4-ylamino)-benzamides
CN114591299A (en) Paroviride intermediate and preparation and application thereof
CN104292133B (en) The synthetic method of a kind of cancer therapy drug Vorinostat
CN1378538A (en) Diazocine-diketone derivatives and use as tryptase inhibitor thereof
CN113754587A (en) Phenylpyrazole compound and application thereof
WO2016107227A1 (en) Pyrrole amide compound, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant